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WORKSHOP OBJECTIVE: The purpose of this work-
shop is to enhance decision-making skills by successfully
applying pharmacoeconomic assessments and the exami-
nation of outcomes research specific to the community
healthcare facility.
PARTICIPANTS WHO WOULD BENEFIT: Health-
care professionals and decision-makers who provide
healthcare from community healthcare facilities.
Community healthcare providers can greatly enhance pa-
tient focused and economic outcomes by performing
their own pharmacoeconomic and outcome studies. Most
community healthcare facilities make decisions based
upon other previous studies that may not reflect their pa-
tient population, community or economic model. This
workshop will enable the participant to identify and ob-
tain vital information that is specific for their facility and
patient population. Incorporating this data into the deci-
sion process will result in developing policy that is more
effective for their facility and community.
WMM5
USING EPIDEMIOLOGIC DATABASES TO 
EXTRAPOLATE LONG-TERM OUTCOMES FROM 
SURROGATE MARKER DATA
Huse DM, Russell, MW
Medical Research International, Burlington, MA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to review the methodological issues involved in
the development of pharmacoeconomic models for pre-
ventive interventions or chronic disease treatments when
the drug’s effects are observed over relatively short time
frames (as in most clinical trials).
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who want to understand how external sources of epi-
demiologic data can be used in conjunction with “surro-
gate marker” data from clinical trials to infer long-term
patient outcomes.
The extended duration of follow-up in large-scale “event”
trials permits researchers to document a drug’s proximal
effects on key biologic measures or “surrogate markers”
and to attribute improvements in long-term patient out-
comes to the drug’s effect on the surrogate marker(s).
While the ability to link short-term effects with long-term
outcomes within a clinical trial is desirable, such studies
are frequently cost-prohibitive. Despite the lack of long-
term follow-up in traditional drug efficacy trials, it is still
possible in many cases to make inferences about a drug’s
long-term effects on patient outcomes. In this workshop,
we will illustrate how statistical models of the relationship
between surrogate markers and outcomes can be devel-
oped using epidemiologic databases, and how these mod-
els can be used in conjunction with surrogate marker and
cost data to estimate long-term clinical and economic con-
sequences of drug therapy. The importance of appropriate
patient identification and selection criteria in epidemio-
logic research will be stressed. A case study will be pre-
sented in which cardiovascular risk equations derived
from the Framingham Heart Study database are used to
estimate reductions in cardiovascular event occurrence
over 1-, 5-, and 10-year time horizons resulting from dec-
rements in diastolic blood pressure (a common surrogate
marker in clinical trials of anti-hypertensive medications).
WMS2
PITFALLS WHEN USING REGRESSION 
EQUATIONS TO ESTIMATE TREATMENT 
IMPACT IN ACTUAL PRACTICE
Caro JJ, Huybrechts KF, Klittich WS
Caro Research, Boston, MA, USA
WORKSHOP OBJECTIVE: To demonstrate how regres-
sion equations should and should not be used when esti-
mating the impact of treatment in actual practice.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers interested in using regression equations in economic
models.
Short of local trials, researchers often resort to using risk
equations, derived from large epidemiological or clinical
studies, to forecast the costs and health consequences of a
new treatment in their target population. In many cases,
the mean risk factor values for the target population are
included directly in the risk equation to calculate the “av-
erage” likelihood of disease for that population. This
common approach may however not be justified, as we
will demonstrate in this workshop, using examples based
on the West of Scotland Coronary Prevention Study. The
results derived in this way do not properly reflect the
clustering of risk factors in the population and are very li-
able to give incorrect outcomes. Instead, epidemiological
studies that contain information on the joint risk factor
distribution in a large number of patients, representative
of the target population, should be identified. These pa-
tient level data should be used to simulate individuals one
at a time and the average risk for the cohort should be
derived as the mean of the individuals’ results. Despite
the increased effort required, this is the only proper tech-
nique to accurately predict the effects of treatment in a
population different from the one used to derive the
equations.
WMS5
ASSESSING THE GENERALIZABILITY OF THE 
RESULTS OF MULTINATIONAL TRIALS FOR 
INDIVIDUAL COUNTRIES PARTICIPATING 
IN THE TRIAL
Glick H, Polsky D
University of Pennsylvania, Philadelphia, PA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to discuss methods for evaluating the gener-
alizability of results from multinational trials. We will
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identify techniques for evaluating the results of country-
specific cost-effectiveness ratios derived from such trials.
Participants will learn when it is more appropriate to use
country-specific ratios and when it is more appropriate to
use the more precise pooled (average) ratio for the overall
study to represent these countries’ ratios.
PARTICIPANTS WHO WOULD BENEFIT: Designers,
analysts, and managers of multinational trials as well as
consumers of the results of such trials.
As economic studies are more frequently being per-
formed in multinational trials, the question is raised
whether the results of economic evaluations in these trials
can inform decision-makers in the individual countries in
which the trial was performed? We propose the use of re-
sampling procedures to estimate point estimates and vari-
ances for the angles representing country-specific cost-ef-
fectiveness ratios. These point estimates and variances
are then used to assess the homogeneity of the resulting
ratios. These methods are illustrated using data from two
multinational trials. In one, even though treatment pat-
terns and outcomes differed among the countries, the
treatment effect on costs, effects, and the cost-effective-
ness ratio were homogeneous. In the second, we found
evidence of heterogeneity in these effects. Data currently
being collected in multinational trials can help us under-
stand if the pooled ratio from the trial is representative of
the ratios for the individual countries enrolled in the trial.
WMD3
NEW METHODS OF DATA COLLECTION IN THE 
COMMUNITY-BASED PHYSICIAN SETTING: 
PROCESS AND TECHNOLOGY
Jardina P, Irwin C
Physicians Data Corporation, Atlanta, GA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to discuss and develop skills in formulating
new methods for clinical data collection in the commu-
nity-based physician setting.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who are interested in moving beyond administrative
data for longitudinal outcomes studies, but who are con-
strained by the complexity, time and effort of traditional
clinical data collection methods would benefit from this
workshop.
Data collection is a critical component of pharmacoeco-
nomic and outcomes studies, and is often a key limiter of
study design and scope. This workshop identifies several
methods of clinical data collection in the community-
based physician setting. This information has broad util-
ity, including support of the conduct of pharmacoeco-
nomics and outcomes research. Because dictation and
transcription are the preferred means of documenting pa-
tient encounters, this workshop focuses on the role of
people, process and technology within that environment.
Will physicians change their behavior to support collec-
tion of data elements needed to conduct studies? What
types of technologies are needed to support discrete data
element capture in a dictation/transcription environment?
What is the evolving role the electronic medical record in
data collection? How are electronic data stores utilized to
cost-effectively validate source data? How can one over-
come the challenges of codifying data elements that are
collected in natural language? What is the role of manual
processes in augmenting automated data collection? The
workshop will present and explore practical strategies for
collecting, managing and reporting clinical information in
the community-based physician environment. Data col-
lected through September 1998 on 5865 coronary artery
disease patients will be presented to demonstrate results
from the techniques presented.
WMD4
COMBINING MARKET DATA AND STATED-
PREFERENCE DATA TO ESTIMATE DEMAND 
FOR A NEW PHARMACEUTICAL
Johnson FR, Desvousges WH, Knight TH, Bingham MF
Triangle Economic Research, Durham, NC, USA
WORKSHOP OBJECTIVE: The workshop participants
will develop skills to identify limitations in market data,
to design an SP survey that will remedy the limitations in
market data, and to understand analytical methods that
combine both existing market data and stated-preference
survey data.
PARTICIPANTS WHO WOULD BENEFIT: New drug
developers, pharmaceutical marketers, and others in-
volved in the analysis of pharmaceutical market demand.
Market data for existing pharmaceuticals is useful in
many situations. However, it has limitations. For exam-
ple, market data contains only existing drugs’ sales.
Thus, it can not provide information on the demand for a
new pharmaceutical in a therapeutic class. The usefulness
of market data also may be limited by low variation in
variables of interest or highly correlated product charac-
teristics. In this workshop, the presenters will demon-
strate methods for augmenting reality-based market data
with data derived from an appropriately designed stated
preference (SP) survey. SP surveys provide the opportu-
nity to assess preferences for product attributes that do
not currently exist in the market or for which market
data is limited. Participants will learn how to apply SP
methods by interactively developing a simple SP survey.
The presenters will introduce the methods used in devel-
oping and administering an SP survey and will present
methods of linking market and SP data that exploit the
richness of both data sources. Finally, the presenters will
demonstrate the power of linking market and SP data.
The example estimates predicted sales of a novel drug
that will be introduced in a mature market.
